+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Ustekinumab Biosimilars Market by Indication (Crohn Disease, Psoriasis, Psoriatic Arthritis), Dosage Form (Autoinjector, Prefilled Syringe, Vial), Strength, Distribution Channel, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 197 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6134373
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Exploring the Emerging Ustekinumab Biosimilars Landscape: Key Drivers, Challenges, and Strategic Imperatives Shaping the Future of Biologic Therapies

Ustekinumab, a monoclonal antibody targeting the p40 subunit of interleukins 12 and 23, has emerged as a cornerstone therapy for a range of immune-mediated inflammatory disorders. Its patent expiration across major markets has unlocked a wave of biosimilar development that promises to reshape the biologic treatment landscape. In this introduction, the focus is to delineate the scientific basis for ustekinumab’s mechanism of action and to highlight how biosimilar entrants are navigating the stringent regulatory pathways necessary for market authorization. Moreover, the evolving definitions of biosimilarity and interchangeability are key determinants of how these therapies will integrate into clinical practice.

Furthermore, as healthcare budgets face mounting pressure, the competitive landscape is being redefined by cost-containment imperatives and value-based contracting models. Stakeholders from payers to providers are evaluating how biosimilars of ustekinumab can alleviate budgetary constraints while maintaining therapeutic efficacy and safety. Consequently, manufacturers are engaging in strategic initiatives to demonstrate real-world evidence, incorporate novel delivery devices, and secure favorable formulary positions. This introduction lays the groundwork for a comprehensive exploration of the ensuing chapters, which will delve into transformative shifts, tariff impacts, segmentation dynamics, and actionable strategies for industry leaders navigating this rapidly evolving arena.

Unveiling the Transformative Shifts Redefining the Ustekinumab Biosimilars Arena: Technological Innovations, Competitive Dynamics, and Regulatory Evolution

Over the past two years, the ustekinumab biosimilars arena has witnessed several transformative shifts that are redefining the competitive and regulatory framework. On the regulatory front, the issuance of interchangeability guidance by key health authorities has injected clarity into substitution practices at the pharmacy level, thereby amplifying the potential uptake of these agents. Furthermore, ongoing alignment efforts around reference product characterization are enabling developers to adopt advanced analytical methods and process controls, which in turn are driving manufacturing efficiencies and ensuring product consistency across multiple production sites.

In parallel, technological innovations in formulation and delivery are accelerating market differentiation. The advent of user-friendly autoinjector platforms and prefilled syringes with ergonomic designs is enhancing patient adherence, while alternative vial formats are being optimized for hospital infusion settings. Concurrently, digital health tools that facilitate remote injection tracking and patient support are emerging as value-added services to strengthen stakeholder engagement. As a result, partnerships between biotechnology firms and contract development organizations are becoming increasingly strategic, pooling expertise in cell line development, process scale-up, and quality assurance.

Moreover, the increasingly competitive landscape has been influenced by shifting patent landscapes and evolving legal challenges. Patent cliffs have catalyzed a surge of biosimilar candidates, while litigations around patent validity and exclusivity are shaping entry timelines. This dynamic environment underscores the need for agility in strategic planning and rapid adaptation to both regulatory and legal developments.

Subsequently, market dynamics are being further influenced by evolving payer models that prioritize outcomes-based agreements and indication-specific contracting. These models are compelling developers to furnish robust health economic data and forge collaborations with healthcare systems to demonstrate the long-term value proposition of biosimilar ustekinumab. Taken together, these multi-dimensional shifts are laying the foundation for a new era of accessibility, competition, and innovation within the biologics sphere.

Assessing the Cumulative Impact of United States Tariffs in 2025 on Ustekinumab Biosimilar Trade Flows, Production Cost Structures, and Market Accessibility

By 2025, the United States’ implementation of revised tariff schedules has produced a cumulative impact on the trade and manufacturing economics of ustekinumab biosimilars. Tariff escalations on key inputs such as single-use bioreactor components, chromatography resins, and active pharmaceutical ingredients have incrementally increased production costs for manufacturers reliant on global supply chains. In response, several developers have initiated reshoring strategies or established dual-sourcing agreements to mitigate exposure to trade-related disruptions while preserving margin integrity. These initiatives are contributing to a more geographically diversified manufacturing footprint.

Concurrently, import tariffs on finished drug products have compelled certain biologics developers to reassess their market entry strategies. Instead of a direct importation model, some companies are exploring tolling agreements and co-manufacturing partnerships within the United States to circumvent tariff burdens and expedite local access. These alliances are not only reshaping supply chain architectures but also fostering localized expertise in advanced biologic process development. As a result, stakeholders across the value chain are reevaluating logistics, warehousing, and distribution frameworks to balance cost pressures with service level expectations.

Moreover, the ripple effects of these tariff measures extend to contract negotiations with payers and tendering authorities. Elevated baseline costs have necessitated more sophisticated pricing structures that account for variable import duties. Consequently, companies are leveraging scenario analyses to assess the net pricing impact under different tariff regimes and to identify optimal contracting pathways. Ultimately, the cumulative effect of United States tariff policies in 2025 has underscored the importance of agile supply chain management and proactive stakeholder engagement in navigating a complex trade environment.

Furthermore, the tariff-induced recalibration has spotlighted the necessity for comprehensive risk management frameworks that integrate geopolitical intelligence and probabilistic scenario planning. This holistic approach enables industry leaders to anticipate policy shifts, model cost implications, and design contingency plans that preserve patient access and commercial viability. Such forward-looking strategies are becoming a hallmark of resilient biosimilar portfolios in the face of evolving trade landscapes.

Unraveling Critical Segmentation Insights That Decode Ustekinumab Biosimilars Market Dynamics Across Indications, Dosage Forms, Strengths, Channels, and End Users

An in-depth exploration of segmentation dynamics reveals nuanced demand patterns across multiple dimensions for ustekinumab biosimilars. When evaluated by indication, the biosimilar portfolio must address the heterogeneity of immune-mediated diseases, with Crohn’s disease presenting subtypes such as colonic, ileal, and ileocolonic involvement that may influence dosing regimens and payer perceptions. Similarly, psoriasis manifests in moderate and severe forms, each carrying distinct clinical management pathways and budgetary considerations. In psoriatic arthritis, the asymmetric, spondylitic, and symmetric disease phenotypes exert varying pressures on joint damage mitigation strategies, while ulcerative colitis cases involving left-sided, pancolitis, and proctitis presentations necessitate differentiated therapeutic approaches and evidence frameworks.

Beyond clinical presentation, dosage form selection has emerged as a critical determinant of market penetration. Patient preference trends indicate a growing inclination toward autoinjector devices that streamline home administration, whereas healthcare providers may favor prefilled syringes or vial formats for controlled settings. Strength options further stratify the market, with 45 mg and 90 mg presentations catering to induction and maintenance phases in alignment with label-specific dosing algorithms.

In addition, distribution channels such as hospital pharmacies, online specialty platforms, and retail outlets each offer unique value propositions. Hospital-based dispensing supports institutional contracts and day-one access, whereas online pharmacies are driving convenience-oriented models and real-time inventory management. Meanwhile, retail pharmacies remain integral for chronic care continuity. Lastly, end user engagement varies from home care self-administration settings that prioritize ease of use, to hospital infusion centers that emphasize clinician oversight, and specialty clinics that integrate multidisciplinary support. Collectively, these segmentation insights illuminate the intricate matrix of clinical, operational, and commercial factors shaping biosimilar adoption strategies.

Delineating Key Regional Perspectives on Ustekinumab Biosimilars Adoption Patterns, Reimbursement Frameworks, and Growth Drivers Across Global Territories

Regional variations in healthcare infrastructure, regulatory frameworks, and payer philosophies are pivotal in shaping the adoption trajectory of ustekinumab biosimilars. In the Americas, particularly the United States, a competitive reimbursement landscape driven by value-based procurement has accelerated biosimilar tendering and formulary inclusion. Concurrently, Canada’s public health systems emphasize cost-effectiveness analyses and centralized purchasing, fostering negotiation synergies that can amplify biosimilar uptake. Across Latin America, emerging health technology assessment bodies are gradually instituting evidence-based reimbursement pathways, creating a fertile ground for biosimilar entrants that can demonstrate robust real-world outcomes.

Turning to Europe, the Middle East, and Africa, regulatory harmonization efforts spearheaded by supranational entities have simplified dossier submissions and interchangeability considerations, thereby reducing entry barriers. Western European nations continue to lead in biosimilar integration through structured switching programs, while markets in the Middle East are evolving rapidly through public-private partnerships that enhance market access for reputable manufacturers. In Africa, capacity constraints and fragmented payers pose adoption challenges, yet regional alliances and donor-supported initiatives are beginning to pave the way for cost-sensitive biologic therapy options.

In the Asia-Pacific corridor, diverse policy landscapes coexist, ranging from Japan’s rigorous biosimilarity assessment protocols to China’s expedited approval pathways for qualified domestic developers. Australia’s progressive pharmacoeconomic guidelines are shaping a competitive milieu that rewards affordability and clinical equivalence, whereas Southeast Asian markets are balancing budgetary limitations with growing demand for advanced therapies. In parallel, India’s biopharmaceutical sector is leveraging its manufacturing prowess to secure global partnerships, strengthening supply assurance for both regional consumption and export markets. These regional insights underscore the necessity for tailored market entry strategies that align with local regulatory, economic, and cultural determinants.

Revealing Strategic Positioning and Competitive Differentiators of Leading Ustekinumab Biosimilars Developers and Collaborators in a Crowded Marketplace

Leading stakeholders in the ustekinumab biosimilar space are deploying a range of strategic maneuvers to establish competitive differentiation and secure market share. Incumbent biologics developers are fortifying their pipelines by forging alliances with contract manufacturing organizations to bolster capacity and expedite scale-up operations. Concurrently, nimble biotech firms are capitalizing on process innovation, leveraging high-yield cell lines and continuous downstream purification techniques to drive cost efficiencies. Collaborative licensing agreements are emerging as a common theme, enabling mid-tier players to access proprietary formulation technologies and advanced delivery platforms without incurring the full spectrum of development expenses.

Strategic partnerships between multinational corporations and regional manufacturers are also reshaping distribution networks and reinforcing local market expertise. Through these alliances, companies are gaining greater latitude in navigating complex regulatory landscapes and tailoring go-to-market strategies to specific reimbursement environments. Real-world evidence generation is another focal point; several players are investing in observational studies and patient registries to substantiate the therapeutic equivalence of their biosimilar candidates and facilitate payer negotiations. This emphasis on post-marketing surveillance not only bolsters confidence among prescribers but also underpins long-term pharmacovigilance commitments.

Moreover, device differentiation is playing an increasingly prominent role in competitive positioning. Companies offering autoinjector solutions integrated with digital adherence tracking are positioning themselves favorably among patient-centric healthcare networks. At the same time, established manufacturers are exploring value-added services, such as remote nurse support and patient education modules, to reinforce brand loyalty and reduce therapy discontinuation rates. Collectively, these strategic approaches underscore the multi-faceted efforts by key companies to navigate a crowded and highly regulated marketplace.

Crafting Forward-Looking Actionable Recommendations to Empower Industry Leaders to Capitalize on Emerging Opportunities in the Ustekinumab Biosimilars Domain

As the biosimilars landscape for ustekinumab continues to mature, industry leaders should prioritize flexible manufacturing architectures that can pivot rapidly in response to shifting trade policies and raw material constraints. Investing in modular production systems and dual-sourcing agreements will enhance resilience and enable rapid scale adjustments for anticipated demand surges. In parallel, securing interchangeability designations in principal markets will unlock substitution opportunities at the pharmacy level, catalyzing uptake among cost-conscious stakeholders. Manufacturers are advised to engage proactively with regulatory authorities to clarify interchangeability criteria and expedite filing pathways.

Furthermore, establishing robust real-world evidence programs will be critical to demonstrating sustained efficacy and safety across diverse patient populations. Collaboration with healthcare systems to implement structured switching studies and patient registries will provide the data foundation necessary to underpin value-based contracting models. In addition, device innovation should remain a strategic priority; integrating connectivity features into autoinjector platforms will address patient adherence challenges and reinforce differentiation in a competitive market.

Engagement with payers and providers through multi-stakeholder roundtables will facilitate the alignment of expectations around pricing, reimbursement, and patient support services. Proactive dialogue can also uncover opportunities for indication-specific funding arrangements that reflect the nuanced clinical value proposition across the various disease subtypes. Finally, a comprehensive geopolitical risk management framework should be implemented to anticipate tariff fluctuations and geopolitical tensions. By adopting scenario-based planning and maintaining transparent communication with supply chain partners, organizations can secure supply continuity and safeguard commercial viability.

Illuminating the Rigorous Research Methodology Underpinning the Ustekinumab Biosimilars Market Study Including Data Collection, Validation, and Analytical Approaches

The research underpinning this study on the ustekinumab biosimilars domain is grounded in a systematic and multi-tiered methodology designed to ensure rigor, accuracy, and relevance. Initially, extensive secondary research was conducted, drawing upon peer-reviewed publications, regulatory filings, and publicly available policy documents to construct a foundational understanding of the therapeutic, regulatory, and competitive contexts. Subsequently, a series of in-depth interviews were carried out with key opinion leaders, including clinicians, formulary decision-makers, and manufacturing specialists, to validate secondary data and uncover nuanced insights not readily accessible through desk research.

Following primary research, a structured data triangulation process was applied to harmonize findings across different information streams. This step involved cross-referencing expert perspectives with empirical industry data and regulatory benchmarks, allowing for the resolution of discrepancies and the reinforcement of critical conclusions. In addition, a proprietary analytical framework was utilized to assess market drivers, barrier factors, and strategic imperatives, ensuring that each dimension of the biosimilar ecosystem was examined through both quantitative and qualitative lenses.

To uphold methodological transparency and minimize bias, all assumptions and data sources have been documented and subjected to peer review by a panel of independent subject matter experts. Furthermore, scenario analyses were deployed to explore alternative trajectories under varying policy, economic, and technological conditions. Collectively, this rigorous research methodology provides a credible and actionable foundation for the insights presented throughout this executive summary.

Synthesizing Critical Insights and Strategic Takeaways from the Ustekinumab Biosimilars Executive Summary to Guide Future Decision-Making by Stakeholders

In conclusion, the evolving landscape of ustekinumab biosimilars is characterized by a confluence of regulatory advancements, technological innovations, and pricing dynamics that collectively signal a new paradigm in biologic therapy access. The introduction of interchangeability guidance and harmonized approval frameworks has lowered barriers to entry, while advances in formulation design and digital support services are enhancing patient convenience and treatment adherence. Simultaneously, trade policy developments in the United States have underscored the importance of supply chain agility and risk mitigation strategies.

The segmentation analysis has illuminated the clinical diversity of indications, dosing presentations, distribution pathways, and end user requirements, emphasizing the need for tailored market entry and commercialization strategies. Regional insights reveal that stakeholder expectations and procurement mechanisms vary significantly across the Americas, EMEA, and Asia-Pacific, necessitating localized engagement models. Moreover, competitive positioning among key companies is being shaped by strategic alliances, real-world evidence generation, and device differentiation efforts.

Ultimately, industry leaders that adopt flexible manufacturing frameworks, invest in robust evidence generation programs, and engage proactively with regulatory and payer communities will be best positioned to capture the opportunities inherent in the ustekinumab biosimilars sector. By leveraging the comprehensive insights and actionable recommendations detailed in this summary, stakeholders can navigate the complex ecosystem with confidence and unlock the full potential of biosimilar therapies to deliver clinical and economic value.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Indication
    • Crohn Disease
      • Colonic
      • Ileal
      • Ileocolonic
    • Psoriasis
      • Moderate
      • Severe
    • Psoriatic Arthritis
      • Asymmetric
      • Spondylitis
      • Symmetric
    • Ulcerative Colitis
      • Left-Sided
      • Pancolitis
      • Proctitis
  • Dosage Form
    • Autoinjector
    • Prefilled Syringe
    • Vial
  • Strength
    • 45 Mg
    • 90 Mg
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • End User
    • Home Care
    • Hospital
    • Specialty Clinic
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Coherus BioSciences, Inc.
  • Celltrion, Inc.
  • Fresenius Kabi AG
  • JSC BIOCAD
  • Dr. Reddy’s Laboratories Ltd.
  • Sandoz International GmbH

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Clinical trial outcomes highlighting efficacy and safety of new ustekinumab biosimilars in psoriasis patients
5.2. Regulatory approvals in major markets accelerating launch timelines for ustekinumab biosimilars
5.3. Patent litigation outcomes influencing market entry strategies for ustekinumab biosimilars
5.4. Cost-saving analyses demonstrating health economic impact of ustekinumab biosimilar adoption in dermatology
5.5. Strategic partnerships between biotech firms and universities driving ustekinumab biosimilar R&D innovation
5.6. Market penetration of ustekinumab biosimilars in emerging economies challenging originator market share
5.7. Manufacturing scale-up initiatives to address supply chain constraints for ustekinumab biosimilars
5.8. Real-world evidence studies assessing long-term immunogenicity profiles of ustekinumab biosimilars
5.9. Physician prescribing behavior shifts due to payer-driven preferential reimbursement for ustekinumab biosimilars
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Ustekinumab Biosimilars Market, by Indication
8.1. Introduction
8.2. Crohn Disease
8.2.1. Colonic
8.2.2. Ileal
8.2.3. Ileocolonic
8.3. Psoriasis
8.3.1. Moderate
8.3.2. Severe
8.4. Psoriatic Arthritis
8.4.1. Asymmetric
8.4.2. Spondylitis
8.4.3. Symmetric
8.5. Ulcerative Colitis
8.5.1. Left-Sided
8.5.2. Pancolitis
8.5.3. Proctitis
9. Ustekinumab Biosimilars Market, by Dosage Form
9.1. Introduction
9.2. Autoinjector
9.3. Prefilled Syringe
9.4. Vial
10. Ustekinumab Biosimilars Market, by Strength
10.1. Introduction
10.2. 45 Mg
10.3. 90 Mg
11. Ustekinumab Biosimilars Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Ustekinumab Biosimilars Market, by End User
12.1. Introduction
12.2. Home Care
12.3. Hospital
12.4. Specialty Clinic
13. Americas Ustekinumab Biosimilars Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Ustekinumab Biosimilars Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Ustekinumab Biosimilars Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Coherus BioSciences, Inc.
16.3.2. Celltrion, Inc.
16.3.3. Fresenius Kabi AG
16.3.4. JSC BIOCAD
16.3.5. Dr. Reddy’s Laboratories Ltd.
16.3.6. Sandoz International GmbH
17. ResearchAI18. ResearchStatistics19. ResearchContacts20. ResearchArticles21. Appendix
List of Figures
FIGURE 1. USTEKINUMAB BIOSIMILARS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 8. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY STRENGTH, 2024 VS 2030 (%)
FIGURE 10. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY STRENGTH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS USTEKINUMAB BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS USTEKINUMAB BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES USTEKINUMAB BIOSIMILARS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES USTEKINUMAB BIOSIMILARS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC USTEKINUMAB BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC USTEKINUMAB BIOSIMILARS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. USTEKINUMAB BIOSIMILARS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. USTEKINUMAB BIOSIMILARS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. USTEKINUMAB BIOSIMILARS MARKET: RESEARCHAI
FIGURE 26. USTEKINUMAB BIOSIMILARS MARKET: RESEARCHSTATISTICS
FIGURE 27. USTEKINUMAB BIOSIMILARS MARKET: RESEARCHCONTACTS
FIGURE 28. USTEKINUMAB BIOSIMILARS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. USTEKINUMAB BIOSIMILARS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY CROHN DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY CROHN DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY COLONIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY COLONIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY ILEAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY ILEAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY ILEOCOLONIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY ILEOCOLONIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY CROHN DISEASE, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY CROHN DISEASE, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIASIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY MODERATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY MODERATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY SEVERE, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY SEVERE, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIASIS, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIASIS, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY ASYMMETRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY ASYMMETRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY SPONDYLITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY SPONDYLITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY SYMMETRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY SYMMETRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY LEFT-SIDED, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY LEFT-SIDED, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PANCOLITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PANCOLITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PROCTITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PROCTITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY AUTOINJECTOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY AUTOINJECTOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY VIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY VIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY 45 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY 45 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY 90 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY 90 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS USTEKINUMAB BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS USTEKINUMAB BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS USTEKINUMAB BIOSIMILARS MARKET SIZE, BY CROHN DISEASE, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS USTEKINUMAB BIOSIMILARS MARKET SIZE, BY CROHN DISEASE, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIASIS, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIASIS, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS USTEKINUMAB BIOSIMILARS MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS USTEKINUMAB BIOSIMILARS MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS USTEKINUMAB BIOSIMILARS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS USTEKINUMAB BIOSIMILARS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS USTEKINUMAB BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS USTEKINUMAB BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS USTEKINUMAB BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS USTEKINUMAB BIOSIMILARS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES USTEKINUMAB BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES USTEKINUMAB BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES USTEKINUMAB BIOSIMILARS MARKET SIZE, BY CROHN DISEASE, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES USTEKINUMAB BIOSIMILARS MARKET SIZE, BY CROHN DISEASE, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIASIS, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIASIS, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES USTEKINUMAB BIOSIMILARS MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES USTEKINUMAB BIOSIMILARS MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES USTEKINUMAB BIOSIMILARS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES USTEKINUMAB BIOSIMILARS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES USTEKINUMAB BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES USTEKINUMAB BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES USTEKINUMAB BIOSIMILARS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES USTEKINUMAB BIOSIMILARS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 119. CANADA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 120. CANADA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 121. CANADA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY CROHN DISEASE, 2018-2024 (USD MILLION)
TABLE 122. CANADA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY CROHN DISEASE, 2025-2030 (USD MILLION)
TABLE 123. CANADA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIASIS, 2018-2024 (USD MILLION)
TABLE 124. CANADA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIASIS, 2025-2030 (USD MILLION)
TABLE 125. CANADA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 126. CANADA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 127. CANADA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 128. CANADA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 129. CANADA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 130. CANADA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 131. CANADA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 132. CANADA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 133. CANADA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 134. CANADA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 135. CANADA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 136. CANADA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 137. MEXICO USTEKINUMAB BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 138. MEXICO USTEKINUMAB BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 139. MEXICO USTEKINUMAB BIOSIMILARS MARKET SIZE, BY CROHN DISEASE, 2018-2024 (USD MILLION)
TABLE 140. MEXICO USTEKINUMAB BIOSIMILARS MARKET SIZE, BY CROHN DISEASE, 2025-2030 (USD MILLION)
TABLE 141. MEXICO USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIASIS, 2018-2024 (USD MILLION)
TABLE 142. MEXICO USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIASIS, 2025-2030 (USD MILLION)
TABLE 143. MEXICO USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 144. MEXICO USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 145. MEXICO USTEKINUMAB BIOSIMILARS MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 146. MEXICO USTEKINUMAB BIOSIMILARS MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 147. MEXICO USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 148. MEXICO USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 149. MEXICO USTEKINUMAB BIOSIMILARS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 150. MEXICO USTEKINUMAB BIOSIMILARS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 151. MEXICO USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 152. MEXICO USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 153. MEXICO USTEKINUMAB BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 154. MEXICO USTEKINUMAB BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY CROHN DISEASE, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY CROHN DISEASE, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIASIS, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIASIS, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL USTEKINUMAB BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 173. ARGENTINA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 174. ARGENTINA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY CROHN DISEASE, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY CROHN DISEASE, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIASIS, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIASIS, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY CROHN DISEASE, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY CROHN DISEASE, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIASIS, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIASIS, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM USTEKINUMAB BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 212. UNITED KINGDOM USTEKINUMAB BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM USTEKINUMAB BIOSIMILARS MARKET SIZE, BY CROHN DISEASE, 2018-2024 (USD MILLION)
TABLE 214. UNITED KINGDOM USTEKINUMAB BIOSIMILARS MARKET SIZE, BY CROHN DISEASE, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIASIS, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIASIS, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM USTEKINUMAB BIOSIMILARS MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 220. UNITED KINGDOM USTEKINUMAB BIOSIMILARS MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM USTEKINUMAB BIOSIMILARS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 224. UNITED KINGDOM USTEKINUMAB BIOSIMILARS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 226. UNITED KINGDOM USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM USTEKINUMAB BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 228. UNITED KINGDOM USTEKINUMAB BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 229. GERMANY USTEKINUMAB BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 230. GERMANY USTEKINUMAB BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 231. GERMANY USTEKINUMAB BIOSIMILARS MARKET SIZE, BY CROHN DISEASE, 2018-2024 (USD MILLION)
TABLE 232. GERMANY USTEKINUMAB BIOSIMILARS MARKET SIZE, BY CROHN DISEASE, 2025-2030 (USD MILLION)
TABLE 233. GERMANY USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIASIS, 2018-2024 (USD MILLION)
TABLE 234. GERMANY USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIASIS, 2025-2030 (USD MILLION)
TABLE 235. GERMANY USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 236. GERMANY USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 237. GERMANY USTEKINUMAB BIOSIMILARS MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 238. GERMANY USTEKINUMAB BIOSIMILARS MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 239. GERMANY USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 240. GERMANY USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 241. GERMANY USTEKINUMAB BIOSIMILARS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 242. GERMANY USTEKINUMAB BIOSIMILARS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 243. GERMANY USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 244. GERMANY USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 245. GERMANY USTEKINUMAB BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 246. GERMANY USTEKINUMAB BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 247. FRANCE USTEKINUMAB BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 248. FRANCE USTEKINUMAB BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 249. FRANCE USTEKINUMAB BIOSIMILARS MARKET SIZE, BY CROHN DISEASE, 2018-2024 (USD MILLION)
TABLE 250. FRANCE USTEKINUMAB BIOSIMILARS MARKET SIZE, BY CROHN DISEASE, 2025-2030 (USD MILLION)
TABLE 251. FRANCE USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIASIS, 2018-2024 (USD MILLION)
TABLE 252. FRANCE USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIASIS, 2025-2030 (USD MILLION)
TABLE 253. FRANCE USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 254. FRANCE USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 255. FRANCE USTEKINUMAB BIOSIMILARS MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 256. FRANCE USTEKINUMAB BIOSIMILARS MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 257. FRANCE USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 258. FRANCE USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 259. FRANCE USTEKINUMAB BIOSIMILARS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 260. FRANCE USTEKINUMAB BIOSIMILARS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 261. FRANCE USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 262. FRANCE USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 263. FRANCE USTEKINUMAB BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 264. FRANCE USTEKINUMAB BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 265. RUSSIA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 266. RUSSIA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 267. RUSSIA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY CROHN DISEASE, 2018-2024 (USD MILLION)
TABLE 268. RUSSIA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY CROHN DISEASE, 2025-2030 (USD MILLION)
TABLE 269. RUSSIA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIASIS, 2018-2024 (USD MILLION)
TABLE 270. RUSSIA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIASIS, 2025-2030 (USD MILLION)
TABLE 271. RUSSIA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 272. RUSSIA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 273. RUSSIA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 274. RUSSIA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 275. RUSSIA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 276. RUSSIA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 277. RUSSIA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 278. RUSSIA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 279. RUSSIA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 280. RUSSIA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 281. RUSSIA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 282. RUSSIA USTEKINUMAB BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 283. ITALY USTEKINUMAB BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 284. ITALY USTEKINUMAB BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 285. ITALY USTEKINUMAB BIOSIMILARS MARKET SIZE, BY CROHN DISEASE, 2018-2024 (USD MILLION)
TABLE 286. ITALY USTEKINUMAB BIOSIMILARS MARKET SIZE, BY CROHN DISEASE, 2025-2030 (USD MILLION)
TABLE 287. ITALY USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIASIS, 2018-2024 (USD MILLION)
TABLE 288. ITALY USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIASIS, 2025-2030 (USD MILLION)
TABLE 289. ITALY USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 290. ITALY USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 291. ITALY USTEKINUMAB BIOSIMILARS MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 292. ITALY USTEKINUMAB BIOSIMILARS MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 293. ITALY USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 294. ITALY USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 295. ITALY USTEKINUMAB BIOSIMILARS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 296. ITALY USTEKINUMAB BIOSIMILARS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 297. ITALY USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 298. ITALY USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 299. ITALY USTEKINUMAB BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 300. ITALY USTEKINUMAB BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 301. SPAIN USTEKINUMAB BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 302. SPAIN USTEKINUMAB BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 303. SPAIN USTEKINUMAB BIOSIMILARS MARKET SIZE, BY CROHN DISEASE, 2018-2024 (USD MILLION)
TABLE 304. SPAIN USTEKINUMAB BIOSIMILARS MARKET SIZE, BY CROHN DISEASE, 2025-2030 (USD MILLION)
TABLE 305. SPAIN USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIASIS, 2018-2024 (USD MILLION)
TABLE 306. SPAIN USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIASIS, 2025-2030 (USD MILLION)
TABLE 307. SPAIN USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 308. SPAIN USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 309. SPAIN USTEKINUMAB BIOSIMILARS MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2024 (USD MILLION)
TABLE 310. SPAIN USTEKINUMAB BIOSIMILARS MARKET SIZE, BY ULCERATIVE COLITIS, 2025-2030 (USD MILLION)
TABLE 311. SPAIN USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 312. SPAIN USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 313. SPAIN USTEKINUMAB BIOSIMILARS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 314. SPAIN USTEKINUMAB BIOSIMILARS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 315. SPAIN USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 316. SPAIN USTEKINUMAB BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 317. SPAIN USTEKINUMAB BIOSIMILARS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 318. SPAIN USTEKINUMAB BIOSIMILARS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 319. UNITED ARAB EMIRATES USTEKINUMAB BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 320. UNITED ARAB EMIRATES USTEKINUMAB BIOSIMILARS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 321. UNITED ARAB EMIRATES USTEKINUMAB BIOSIMILARS MARKET SIZE, BY CROHN DISEASE, 2018-2024 (USD MILLION)
TABLE 322. UNITED ARAB EMIRATES USTEKINUMAB BIOSIMILARS MARKET SIZE, BY CROHN DISEASE, 2025-2030 (USD MILLION)
TABLE 323. UNITED ARAB EMIRATES USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIASIS, 2018-2024 (USD MILLION)
TABLE 324. UNITED ARAB EMIRATES USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIASIS, 2025-2030 (USD MILLION)
TABLE 325. UNITED ARAB EMIRATES USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2024 (USD MILLION)
TABLE 326. UNITED ARAB EMIRATES USTEKINUMAB BIOSIMILARS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2025-2030 (USD MILLION)
TABLE 327. UNITED ARAB EMIRATES USTEKINUMAB BIOSIMILARS MARKET SIZE, BY ULCERATIVE COLITIS

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Ustekinumab Biosimilars Market report include:
  • Coherus BioSciences, Inc.
  • Celltrion, Inc.
  • Fresenius Kabi AG
  • JSC BIOCAD
  • Dr. Reddy’s Laboratories Ltd.
  • Sandoz International GmbH